Chronic hepatitis B a guideline to diagnosis, approach, management, and follow-up 2007 Turkish association for the study of liver

Turkish Journal of Gastroenterology

Volumn 19, Issue 4, 2008, Pages 207-230

  Akarca, Ulus Salih ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ADEFOVIR; ALANINE AMINOTRANSFERASE; ANTIVIRUS AGENT; ENTECAVIR; HEPATITIS B ANTIGEN; HEPATITIS B VACCINE; LAMIVUDINE; PEGINTERFERON; TENOFOVIR;

ADD ON THERAPY; ALANINE AMINOTRANSFERASE BLOOD LEVEL; CANCER DIAGNOSIS; CANCER RISK; CHRONIC HEPATITIS; CLINICAL FEATURE; CONFERENCE PAPER; DISEASE COURSE; DRUG EFFICACY; FOLLOW UP; HEALTH CARE PERSONNEL; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOSUPPRESSIVE TREATMENT; LIVER BIOPSY; LIVER CELL CARCINOMA; LIVER FAILURE; PRACTICE GUIDELINE; PREGNANCY OUTCOME; PREVALENCE; PROGNOSIS; SCREENING TEST; SEXUAL TRANSMISSION; TREATMENT RESPONSE; VACCINATION; VIRUS RESISTANCE; VIRUS TRANSMISSION;

HEPATITIS B, CHRONIC; HUMANS; MASS SCREENING; SOCIAL PROBLEMS; TURKEY;

EID: 58149089434     PISSN: 13004948     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (121)

1. Özdemir D, Kurt H. Hepatit B virus infeksiyonlarinin epidemiyolojisi. Viral Hepatit 2007, Ed Tabak F, Balik İ, Tekeli E. Viral Hepatit Savaşim Derneǧi Yayini, Ankara, 2007, 108-17.
2. Yim HJ, Lok AS. Natural history of chronic hepatitis B virus infection: what we knew in 1981 and what we know in 2005. Hepatology 2006;43:173-81.
3. Çakaloǧlu Y, Kaymakoǧlu S, Ökten A, et al. Horizontal transmission of hepatitis B virus infection. J Hepatol 1992;15:265-6.
4. Deǧertekin H, Tuzcu A, Yalçin K. Horizontal transmission of HBV infection among students in Turkey. Public Health 2000;114:411-2.
5. Özsoylu S. Horizontal transmission of HBsAg in children. J Pediatr Gastroenterol Nutr 1993;17:346-7.
6. Deǧertekin H. Türkiye'de HBV epidemiyolojisi ve bulaşma yollari. Hepatit B Ulusal Uzlaşi Kitabi. 2003;99-110.
7. Sünbül M, Leblebicioglu H. Distribution of hepatitis B virus genotypes in patients with chronic hepatitis B in Turkey. World J Gastroenterol 2005;11:1976-80.
8. Yalçin K, Deǧertekin H, Bahçecioǧlu IH, et al. Hepatitis B virus genotype D prevails in patients with persistently elevated or normal ALT levels in Turkey. Infection 2004;32:24-9.
9. Bozdayi G, Türkyilmaz AR, İdilman R, et al. Complete genome sequence and philogenetic analysis hepatitis B virus isolated from turkish patients with chroronic HBV infection. J Med Virol 2005;76:476-81.
10. Mast EE, Weinbaum CM, Fiore AE, Advisory Committee on Immunization Practices (ACIP) Centers for Disease Control and Prevention (CDC). A comprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United States: recommendations of the Advisory Committee on Immunization Practices (ACIP) Part II: immunization of adults. MMWR Recomm Rep 2006;55:1-33.
11. U. S. Preventive Services Task Force. Screening for Hepatitis B Virus Infection. wwwahrqgov/clinic/uspstf/usp-shepbhtm 2004.
12. Alter MJ, Evatt BL, Margolis HS, et al. Public Health Service inter-agency guidelines for screening donors of blood, plasma, organs, tissues, and semen for evidence of hepatitis B and hepatitis C. MMWR Recomm Rep 1991;40:1-17.
13. Chang MH, Hsu HY, Hsu HC, et al. The significance of spontaneous hepatitis e antigen seroconversion in childhood: with special emphasis on the clearance of hepatitis e antigen before 3 years of age. Hepatology 1995;22:1387-92.
14. Liaw YF, Tsai SL. Pathogenesis and clinical significance of spontaneous exacerbations and remissions in chronic HBV infection. Viral Hepatitis Rev 1997;3:143-54.
15. McMahon BJ, Holck P, Bulkow L, Snowball M. Serologic and clinical outcomes of 1536 Alaska natives chronically infected with hepatitis B virus. Ann Intern Med 2001;135:759-68.
16. Huang MA, Lok ASF. Natural history of hepatitis B and outcomes after liver transplantation. Clinics Liver Dis 2003;7:521-36.
17. Brunetto MR, Oliveri F, Coco B, et al. Outcome of anti-HBe positive chronic hepatitis B in alphainterferon treated and untreated patients: a long term cohort study. J Hepatol 2002;36: 263-70.
18. Hsu Y, Chien RN, Yeh CT, et al. Long-term outcome after spontaneous HBeAg seroconversion in patients with chronic hepatitis B. Hepatology 2002;35:1522-7.
19. De Franchis R, Meucci G, Vecchi M. The natural history of asymptomatic hepatitis B surface antigen carriers. Ann Intern Med 1993;118:191-4.
20. Manno M, Camma C, Schepis F, et al. Natural history of chronic HBV carriers in northern Italy: morbidity and mortality after 30 years. Gastroenterology 2004;127:756-63.
21. Chen CJ, Yang HI, Su J, et al. REVEAL-HBV Study Group. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 2006;295:65-73.
22. Iloeje UH, Yang HI, Su J. Risk Evaluation of Viral Load Elevation and Associated Liver Disease/Cancer-In HBV (the REVEAL-HBV) Study Group. Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroenterology 2006;130: 678-86.
23. Chen G, Lin W, Shen F, et al. Past HBV viral load as predictor of mortality and morbidity from HCC and chronic liver disease in a prospective study. Am J Gastroenterol 2006;101:1797-803.
24. Yuen MF, Tanaka Y, Shinkai N, et al. Risk for hepatocellular carcinoma with respect to hepatitis B virus genotypes B/ C, specific mutations of enhancer II/ core promoter/ precore regions and HBV DNA levels. Gut 2007 May 4; (in press).
25. Sakugawa H, Nakasone H, Nakayoshi T, et al. Preponderance of hepatitis B virus genotype B contributes to a better prognosis of chronic HBV infection in Okinawa, Japan. J Med Virol 2002;67:484-9.
26. Sumi H, Yokosuka O, Seki N, et al. Influence of hepatitis B virus genotypes on the progression of chronic type B liver disease. Hepatology 2003;37:19-26.
27. Sanchez-Tapias JM, Costa J, et al. Influence of hepatitis B virus genotype on the long-term outcome of chronic hepatitis B in western patients. Gastroenterology 2002;123: 1848-56.
28. Gish RG, Locarnini SA. Chronic hepatitisB: Current testing strategies. Clin Gastroenterol Hepatol 2006;4:666-76.
29. Gaia S, Marzano A, Olivero A, et al. Inactive hepatitis B virus carriers: a favourable clinical condition. Eur J Gastroenterology& Hepatology 2005;17:1435-6.
30. Villeneuve J-P. The natural history of chronic hepatitis B virus infection. J Clin Virology 2005;34:139-42.
31. Ikeda K, Arase Y, Saitoh S, et al. Long-term outcome of HBV carriers with negative HBe antigen and normal aminotransferase. Am J Med 2006;119:977-85.
32. Chien YC, Jan CF, Kuo HS, Chen CJ: Nationwide Hepatitis B vaccination program in Taiwan: effectiveness in the 20 years after it was launched. Epidemiol Rev 2006;28:126.
33. Chang MH, Shau WY, Chen CJ, et al. Taiwan Childhood Hepatoma Study Group. Hepatitis B vaccination and hepatocellular carcinoma rates in boys and girls. JAMA 2000;284:3040-2.
34. Poland GA, Jacobson RM: Prevention of hepatitis B with the hepatitis B vaccine. N Engl J Med 2004;351:2832.
35. Shepard CW, Simard EP, Finelli L, et al. Hepatitis B virus infection: epidemiology and vaccination. Epidemiol Rev 2006;28:112-25.
36. Kane M, Banatvala J, Da Villa G, et al. Are booster immunisations needed for lifelong hepatitis B immuity? Lancet 2000;355:561-5.
37. Deguchi M, Yamashita N, Kagita M, et al. Quantitation of hepatitis B surface antigen by an automated chemiluminescent microparticle immunoassay. J Virol Methods 2004;115:217-22.
38. Hatzakis A, Magiorkinis E, Haida C. HBV virological assessment. J Hepatol 2006;44:71-6.
39. Biswas R, Tabor E, Hsia CC, et al. Comparative sensitivity of HBV NATs and HBsAg assays for detection of acute HBV infection. Transfusion 2003;43:788-98.
40. Scheiblauer H, Soboll H, Nick S. Evaluation of 17 CE-marked HBsAg assays with respect to clinical sensitivity, analytical sensitivity, and hepatitis B virus mutant detection. J Med Virol 2006;78:66-70.
41. Manesis EK, Papatheodoridis GV, Sevastianos V, et al. Significance of hepatitis B viremia level determined by quantitative PCR assay in patients with HBeAg negative chronic hepatitis B virus infection. Am J Gastroenterol 2003;98:2261-7.
42. Osiowy C, Villeneuve JP, Heathcote EJ, et al. Detection of rtN236T and rtA181V/T mutations associated with resistance to adefovir dipivoxil in samples from patients with chronic hepatitis B virus infection by the INNO-LiPA HBV DR line probe assay (version 2). J Clin Microbiol 2006;44:1994-7.
43. Kimura T, Rokuhara A, Matsumoto A, et al. New enzyme immunoassay for detection of hepatitis B virus core antigen (HBcAg) and relation between levels of HBcAg and HBV DNA. J Clin Microbiol 2003;41:1901-6.
44. Poynard T, Zoulim F, Ratziu V, et al. Longitudinal assessment of histology surrogate markers (FibroTest-ActiTest) during lamivudine therapy in patients with chronic hepatitis B infection. Am J Gastroenterol 2005;100:1970-80.
45. Sebastiani G, Vario A, Guido M, Alberti A. Sequential algorithms combining non-invasive markers and biopsy for the assessment of liver fibrosis in chronic hepatitis B. World J Gastroenterol 2007;13:525-31.
46. Colloredo G, Guido M, Sonzogni A, Leandro G. Impact of liver biopsy size on histological evaluation of chronic viral hepatitis: the smaller the sample, the milder the disease. J Hepatol 2003;39:239-44
47. Rousselet MC, Michalak S, Dupré F, et al. Hepatitis Network 49. Sources of variability in histological scoring of chronic viral hepatitis. Hepatology 2005;41:257-64.
48. Chu CJ, Hussain M, Lok AS. Quantitative serum HBV DNA levels during different stages of chronic hepatitis B infection. Hepatology 2002;36:1408-15.
49. Liaw YF, Chu CM, Su IJ, et al. Clinical and histological events preceding hepatitis B e antigen seroconversion in chronic type B hepatitis. Gastroenterology 1983;84:216-9.
50. Lok AS, Lai CL, Wu PC, et al. Spontaneous hepatitis B e antigen to antibody seroconversion and reversion in Chinese patients with chronic hepatitis B virus infection. Gastroenterology 1987;92:1839-43.
51. Uzunalimoǧlu Ö, Yurdaydin C, Çetinkaya H, et al. Risk factors for hepatocellular carcinoma in Turkey. Dig Dis Sci 2001;46:1022-8.
52. Günşar F, Akyildiz M, Ersöz G, et al. Hepatosellüler kanserli hastalarin özellikleri. 5. Ulusal Hepatoloji Kongresi Kitabi 2005.
53. Bruix J, Sherman M; Practice Guidelines Committee, American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma. Hepatology 2005;42:1208-36.
54. Beasley RP, Hwang LY, Lin CC, Chien CS. Hepatocellular carcinoma and hepatitis B virus. A prospective study of 22 707 men in Taiwan. Lancet 1981;2:1129-33.
55. Yu MW, Chang HC, Liaw YF, et al. Familial risk of hepatocellular carcinoma among chronic hepatitis B carriers and their relatives. J Natl Cancer Inst 2000;92:1159-64.
56. Hoofnagle JH, Doo E, Liang TJ, et al. Management of hepatitis B: summary of a clinical research workshop. Hepatology.
57. Fung AK, Lok ASF. Treatment of chronic hepatitis: Who to treat, what to use, and for how long? Gastroenterology 2004;2:839-48.
58. Keeffe EB, Dieterich DT, Han SH, et al. A treatment algorithm for the management of chronic hepatitis B virus infection in the United States. Clin Gastroenterol Hepatol 2004;2:87-106.
59. Di Bisceglie AM, Lai CL, Gane E, et al. Telbivudine GLOBE trial: maximal early HBV suppression is predictive of optimal two-year efficacy in nucleoside treated hepatitis B patients. Hepatology 2006;44(4 Suppl 1):230A.
60. Vardar R, Ersöz G, Günşar F, et al. Kronik B hepatitinde lamivudin tedavisi sirasindaki HBV DNA deǧişiminin 24üncü aydaki HBV DNA durumunu öngörme deǧeri. Hepatoloji 2007 Kongresi Abstrakti.
61. van Zonneveld M, Zondervan PE, Cakaloǧlu Y, et al. HBV 99-01 Study Group. Peg-interferon improves liver histology in patients with HBeAg-positive chronic hepatitis B: no additional benefit of combination with lamivudine. Liver Int 2006;26:399-405.
62. Lai CL, Leung N, Teo EK, et al. Telbivudine Phase II Investigator Group. A 1-year trial of telbivudine, lamivudine, and the combination in patients with hepatitis B e antigen-positive chronic hepatitis B. Gastroenterology 2005;129:528-36.
63. Sasadeusz JJ, Locarnini SL, Macdonald G. Why do we not yet have combination chemotherapy for chronic hepatitis B? Med J Aust 2007;186:204-6.
64. Bonino F, Marcellin P, Lau GK, et al. Peginterferon Alfa-2a HBeAg-Negative Chronic Hepatitis B Study Group. Predicting response to peginterferon alpha-2a, lamivudine and the two combined for HBeAg-negative chronic hepatitis B. Gut 2007;56:699-705.
65. Fung SK, Fontana RJ. Management of drug-resistant chronic hepatitis B. Clin Liver Dis 2006;10:275-302.
66. Fung SK, Lok AS. Management of hepatitis B patients with antiviral resistance. Antivir Ther 2004;9:1013-26.
67. Lampertico P, Vigano M, Manenti E, et al. Adefovir rapidly suppresses hepatitis B in HBeAg-negative patients developing genotypic resistance to lamivudine. Hepatology 2005;42:1414-9.
68. Chan HL, Wong VW, Tse CH, et al. Early virological suppression is associated with good maintained response to adefovir dipivoxil in lamivudine resistant chronic hepatitis B. Aliment Pharmacol Ther 2007;25:891-8.
69. Locarnini S, Qi X, Arterburn S, et al. Incidence and predictors of emergence of adefovir resistant HBV during four years of adefovir dipivoxil (ADV) therapy for patients with chronic hepatitis B (CHB). J Hepatol 2005;42(Suppl 2):17.
70. Hsieg TH, Liu CJ, Chen DS, Chen PJ. Naturel course and treatment of hepatitis D virus infection. J Formos Med Assoc 2006;105:869-81.
71. Niro GA, Rosina F, Rizzetto M. Treatment of hepatitis D. J Viral Hepatitis 2005;12:2-9.
72. Farci P, Roskams T, Chessa L, et al. Long-term benefit of interferon alpha therapy of chronic hepatitis D: regression of advanced hepatic fibrosis. Gastroenterology 2004;126:1740-9.
73. Örmeci N. Short- and long- term effects of treatment of chronic hepatitis B and delta virus by IFN. Fund Clinical Pharmacol 2003;17:651-8.
74. Perumalswami PV, Bini EJ. Epidemiology, natural history, and treatment of hepatitis B virus and hepatitis C virus co-infection. Minerva Gastroenterol Dietol 2006;52:145-55.
75. Crockett SD, Keeffe EB. Natural history and treatment of hepatitis B virus and hepatitis C virus coinfection. Ann Clin Microbiol Antimicrob 2005;4:13.
76. Di Martino V, Thevenot T, Colin JF, et al. Influence of HIV infection on the response to interferon therapy and the long-term outcome of chronic hepatitis B. Gastroenterology 2002;123:1812-22.
77. Benhamou Y, Bochet M, Thibault V. Long-term incidence of hepatitis B virus resistance to lamivudine in human immunodeficiency virus-infected patients. Hepatology 1999;30:1302-6.
78. Matthews GV, Bartholomeusz A, Locarnini S, et al. Characteristics of drug resistant HBV in an international collaborative study of HIV-HBV-infected individuals on extended lamivudine therapy. AIDS 2006;20:863-70.
79. Dore GJ, Cooper DA, Barrett C, et al. Dual efficacy of lamivudine treatment in human immunodeficiency virus/hepatitis B virus-coinfected persons in a randomized, controlled study (CAESAR). The CAESAR Coordinating Committee. J Infect Dis 1999;180:607-13.
80. Dore GJ, Cooper DA, Pozniak AL, et al. 903 Study Team; 907 Study Team. Efficacy of tenofovir disoproxil fumarate in antiretroviral therapy-naive and -experienced patients coinfected with HIV-1 and hepatitis B virus. J Infect Dis 2004;189:1185-92.
81. Benhamou Y, Thibault V, Vig P, et al. Safety and efficacy of adefovir dipivoxil in patients infected with lamivudine-resistant hepatitis B and HIV-1. J Hepatol 2006;44:62-7.
82. Bortolotti F, Jara P, Crivellaro C, et al. Outcome of chronic hepatitis B in Caucasian children during a 20-year observation period. J Hepatol 1998;29:184-90.
83. Bortolotti F. Treatment of chronic hepatitis B in children. J Hepatol 2003;39(Suppl 1):200-5.
84. Yüce A, Koçak N, Özen H, Gürakan F. Prolonged interferon alpha treatment in children with chronic hepatitis B. Ann Trop Paediatr 2001;21:77-80.
85. Selimoǧlu MA, Aydoǧdu S, Ünal F, et al. Alpha interferon and lamivudine combination therapy for chronic hepatitis B in children. Pediatr Int 2002;44:404-8.
86. Gürakan F, Koçak N, Özen H, Yüce A. Comparison of standard and high dosage recombinant interferon alpha 2b for treatment of children with chronic hepatitis B infection. Pediatr Infect Dis J 2000;19:52-6.
87. Özgenç F, Arikan C, Sertoz RY, et al. Effect of long-term lamivudine in chronic hepatitis B virus-infected children. Antivir Ther 2004;9:729-32.
88. Dikici B, Özgenç F, Kalayci AG, et al. Current therapeutic approaches in childhood chronic hepatitis B infection: a multicenter study. J Gastroenterol Hepatol 2004;19:127-33.
89. Kansu A, Doǧanci T, Akman SA, et al. Comparison of two different regimens of combined interferon-alpha2a and lamivudine therapy in children with chronic hepatitis B infection. Antivir Ther 2006;11:255-61.
90. Wai CT, Fontana RJ, Polson J, et al. The US Acute Liver Failure Study Group. Clinical outcome and virological characteristics of hepatitis B-related acute liver failure in the United States. J Viral Hepat 2005;12:192-8.
91. Kondili LA, Osman H, Mutimer D. The use of lamivudine for patients with acute hepatitis B (a series of cases). J Viral Hepat 2004;11:427-31.
92. Schmilovitz-Weiss H, Ben-Ari Z, Sikuler E, et al. Lamivudine treatment for acute severe hepatitis B: a pilot study. Liver Int 2004;24:547-51.
93. Tillmann HL, Hadem J, Leifeld L, et al. Safety and efficacy of lamivudine in patients with severe acute or fulminant hepatitis B. A multicenter experience. J Viral Hepat 2006;13:256-63.
94. Kumar M, Satapathy S, Monga R, et al. A randomized controlled trial of lamivudine to treat acute hepatitis B. Hepatology 2007;45:97-101.
95. Perrillo RP. Acute flares in chronic hepatitis B: the natural and unnatural history of an immunologically mediated liver disease. Gastroenterology 2001;120:1009-22.
96. Yuen MF, Yuan HJ, Hui CK. A large population study of spontaneous HBeAg seroconversion and acute exacerbation of chronic hepatitis B infection: implications for antiviral therapy. Gut 2003;52:416-9.
97. Honkoop P, de Man RA, Niesters HG, et al. Acute exacerbation of chronic hepatitis B virus infection after withdrawal of lamivudine therapy. Hepatology 2000;32:635-9.
98. Bain VG, Kneteman NM, Ma MM, et al. Efficacy of lamivudine in chronic hepatitis B patients with active viral replication and decompensated cirrhosis undergoing liver transplantation. Transplantation 1996;62:1456-62.
99. Kim WR, Poterucha JJ, Kremers WK, et al. Outcome of liver transplantation for hepatitis B in the United States. Liver Transpl 2004;10:968-74.
100. Villeneuve JP, Condreay LD, Willems B, et al. Lamivudine treatment for decompensated cirrhosis resulting from chronic hepatitis B. Hepatology 2000;31:207-10.
101. Schiff ER, Lai CL, Hadziyannis S, et al. Adefovir Dipovoxil Study 435 International Investigators Group. Adefovir dipivoxil therapy for lamivudine-resistant hepatitis B in pre- and post-liver transplantation patients. Hepatology 2003;38:1419-27.
102. Markowitz JS, Martin P, Conrad AJ, et al. Prophylaxis against hepatitis B recurrence following liver transplantation using combination lamivudine and hepatitis B immune globulin. Hepatology 1998;28:585-9.
103. Steinmuller T, Seehofer D, Rayes N, et al. Increasing applicability of liver transplantation for patients with hepatitis B-related liver disease. Hepatology 2002;35:1528-35.
104. Marzano A, Salizzoni M, Debernardi-Venon W, et al. Prevention of hepatitis B virus recurrence after liver transplantation in cirrhotic patients treated with lamivudine and passive immunoprophylaxis. J Hepatol 2001;34:903-10.
105. Yoshida EM, Erb SR, Partovi N, et al. Liver transplantation for chronic hepatitis B infection with the use of combination lamivudine and low-dose hepatitis B immune globulin. Liver Transpl Surg 1999;5:520-5.
106. Karasu Z, Özacar T, Akyildiz M, et al. Low-dose hepatitis B immune globulin and higher-dose lamivudine combination to prevent hepatitis B virus recurrence after liver transplantation. Antivir Ther 2004;9:921-27.
107. Chan TM, Fang GX, Tang CS, et al. Preemptive lamivudine therapy based on HBV DNA level in HBsAg-positive kidney allograft recipients. Hepatology 2002;36:1246-52.
108. Soderstrom A, Norkrans G, Lindh M. Hepatitis B virus DNA during pregnancy and post partum: aspects on vertical transmission. Scand J Infect Dis 2003;35:814-19.
109. Xu DZ, Yan YP, Choi BC, et al. Risk factors and mechanism of transplacental transmission of hepatitis B virus: a case-control study. J Med Virol 2002;67:20-6.
110. Raimondo G, Tanzi E, Brancatelli S, et al. Is the course of perinatal hepatitis B virus infection influenced by genetic heterogeneity of the virus? J Med Virol 1993;40:87-90.
111. Xu Q, Xiao L, Lu XB, et al. Cai X. A randomized controlled clinical trial: interruption of intrauterine transmission of hepatitis B virus infection with HBIG. World J Gastroenterol 2006;12:3434-7.
112. Yuan J Antepartum immunoprophylaxis of three doses of Hepatitis B immoglobulin is not effective: a single-centre randomized study. J Viral Hep 2006,13:597-604 1A.
113. Xiao XM, Li AZ, Chen X, et al. Prevention of vertical hepatitis B transmission by hepatitis B immunoglobulin in the third trimester of pregnancy. Int J Gynaecol Obstet 2007;96:167-70.
114. van Zonneveld M, van Nunen AB, Niesters HG, et al. Lamivudine treatment during pregnancy to prevent perinatal transmission of hepatitis B virus infection. J Viral Hepat 2003;10:294-7.
115. Su GG, Pan KH, Zhao NF, et al. Efficacy and safety of lamivudine treatment for chronic hepatitis B in pregnancy. World J Gastroenterol 2004;10: 910-2.
116. Gordon A, McLean CA, Pedersen JS, et al. Hepatic steatosis in chronic hepatitis B and C:predictors, distribution and effect on fibrosis. J Hepatol 2005;43:38-44.
117. Gelatti U, Covolo L, Franceschini M, et al. Brescia HCC Study Group. Coffee consumption reduces the risk of hepatocellular carcinoma independently of its etiology: a case-control study. J Hepatol 2005;42:528-34.
118. Tözün N, Forbes A, Anderson MG, Murray-Lyon IM. Safety of alcohol after viral hepatitis. Lancet 1991;337:1079-80.
119. Ribes J, Cleries R, Rubio A, et al. Cofactors associated with liver disease mortality in an HBsAg-positive Mediterranean cohort: 20 years of follow-up. Int J Cancer 2006;119:687-94.
120. Ritland S, Petlund CF, Knudsen T, Skrede S. Improvement of physical capacity after long-term training in patients with chronic active hepatitis. Scand J Gastroenterol 1983;8:1083-7.
121. Takiguchi F. The effects of exercise on liver function in patients with chronic liver disease. Nippon Ika Daigaku Zasshi 1989;56:132-43.